Shilpa Medicare jumps after arm achieves USFDA milestone for rare blood cancer drugShilpa Medicare jumps after arm achieves USFDA milestone for rare blood cancer drug

Introduction

Leading pharmaceutical group achieved FDA Orphan Drug Designation for its biologic targeting rare blood cancers ET and PV, enabling regulatory incentives and advancing clinical development plans.

Also Read: Poonawalla Fincorp deepens AI-first strategy with five enterprise AI launches

Share price movement of Shilpa Medicare

On January 29, 2026, Shilpa Medicare Ltd opened at ₹274.10, up 0.40% from its previous close of ₹273.00. The stock reached a high of ₹275.00 (0.73%) and a low of ₹268.45 (-1.67%). By 11:45 AM, it traded at ₹269.95, a 1.12% decrease, with a market cap of ₹5,279.73 crore.

Shilpa Medicare Secures FDA Orphan Designation

Shilpa Biologicals Pvt Ltd, a subsidiary of Shilpa Medicare, and mAbTree Biologics AG received U.S. FDA Orphan Drug Designation for their investigational biologic targeting rare blood cancers ET and PV.

The designation recognizes the seriousness of Essential Thrombocythemia and Polycythemia Vera, offering regulatory incentives such as development support, tax credits, and market exclusivity upon eventual approval.

The biologic targets an underexplored immune-evasion pathway, aiming for durable disease control. Shilpa Biologicals and mAbTree will advance IND-enabling studies toward first-in-human clinical trials.

Stock performance of Shilpa Medicare for Period of 1 week, 6 months, and 1 year

Shilpa Medicare Ltd delivered a 1.33% return over the past week, declined 36.2% over six months, and dropped 24.3% over the past 1 year.

Also Read: ABB India gains 5% after winning major traction order for Mumbai Metro expansion

Shareholding pattern of Shilpa Medicare

Particulars	Dec 2025	Sep 2025	Jun 2025
Promoter	40.10%	44.20%	44.20%
FII	11.00%	10.90%	11.20%
DII	8.30%	7.70%	7.50%
Public	40.60%	37.20%	37.10%

About Shilpa Medicare

Shilpa Biologicals Pvt Ltd, part of Shilpa Medicare Group (NSE: SHILPAMED), is a global biopharmaceutical company specializing in discovery, development, and manufacturing of innovative biologics.

Stay Ahead with the Latest Stock Market Updates – Click Here

Disclaimer: The above article is written for educational purposes, and the companies’ data mentioned in the article may change with respect to time. The securities quoted are exemplary and are not recommendatory.

FAQs